1. Introduction
Suicidal behavior is a major public health concern, ranking as the second leading cause of death among adolescents and young adults (Suicide Prevention: Facts About Suicide. Centers for Disease Control and Prevention; 2023). It is a complex and diverse condition that includes suicidal ideation, suicide attempt, and death by suicide. A deeper understanding of the biology and pathology underlying suicidal behavior is essential for developing effective prevention strategies and remains a critical public health priority. Current models suggest that suicide attempts and completed suicides result from interactions between individual vulnerabilities and external stressors [1]. At the individual level, triggers may include recent stressful life events and the presence of psychiatric conditions. Mental health disorders, particularly bipolar disorder (BD), major depressive disorder (MDD), and schizophrenia (SCH), are strongly associated with increased risk of suicide attempt. Individuals with these conditions have been shown to have a suicide mortality rate approximately ten times higher than that of the general population [2]. Evidence from family, twin, and adoption studies suggests a genetic contribution to suicidal behavior, and its interaction with environmental factors [3,4]. Individuals with a family history of suicidal behavior have approximately five times higher risk [3]. Twin studies show greater concordance in identical twins, with heritability estimates up to 45%, while adoption studies reveal a sevenfold increased risk of completed suicide among biological relatives [3].
Post-mortem studies of individuals who died by suicide have revealed consistent alterations in the serotonin (5-HT) system [5,6,7,8]. These include reduced numbers of 5-HT transporter sites, changes in the number and structure of 5-HT-producing neurons in the brainstem, lower binding affinity of 5-HT transporters and receptors, and decreased 5-HT responsiveness [9,10,11,12]. Additionally, reduced levels of the primary metabolic product of 5-HT, 5-hydroxyindoleacetic acid (5-HIAA), have been found in the cerebrospinal fluid (CSF) of suicide victims [9,10,11,13,14,15]. However, due to the design of these studies, it is difficult to determine whether the observed changes are associated with suicide itself or with the underlying psychiatric disorders.
Multiple genetic variants within 5-HT system genes have been associated with suicidal behavior through candidate gene studies [1,6,16]. Recent genetic studies, including genome-wide association studies (GWAS) [17,18,19,20] and Mendelian randomization analyses [21,22,23], provide complementary insights into the genetic pathways influencing psychiatric disorders and suicide attempt risk. Nevertheless, findings from these studies have been inconsistent, largely due to underpowered studies, the reliance of GWAS on statistical associations rather than underlying biological mechanisms, and the oversight of interactions among genetic variants and processes in biological systems.
In our previous work, we developed a computational dynamic model of the 5-HT presynapse that simulates the synthesis, reuptake, and degradation of 5-HT based on individual genetic variants in key 5-HT system genes: TPH2, SLC6A4 and MAOA [24]. The model captures dynamic changes in molecular concentrations throughout the simulation, taking into account the interactions between the elements of the 5-HT presynapse as well as the individual’s genotype-based modulation of enzyme and transporter activity. The model initiates with the uptake of dietary tryptophan into the presynaptic neuron, which is converted to 5-hydroxytryptophan (5-HTP) by the rate-limiting enzyme tryptophan hydroxylase 2 (TPH2), and then further processed into free intracellular serotonin (fc5-HT). The fc5-HT is stored in vesicles as vesicular 5-HT (v5-HT), released into the synaptic cleft as extracellular 5-HT (e5-HT), and either degraded or reabsorbed via the serotonin transporter (SERT, encoded by the SLC6A4 gene). Finally, monoamine oxidase A (MAOA) catalyzes the degradation of fc5-HT into 5-HIAA. The model produces a set of time series that capture the changes in the concentrations of 5-HTP, fc5-HT, v5-HT, e5-HT and 5-HIAA, which are referred to as molecular species [25]. The predicted profiles of these molecular species vary across individuals, depending on their specific genotype combinations. The model has been validated on 140 unaffected individuals and applied to a cohort of patients diagnosed with BD and categorized according to suicide attempt status [24]. We observed lower predicted mean 5-HIAA levels in BD patients with a history of suicide attempt compared to unaffected individuals.
In the present study, we extend the application of our dynamic model of 5-HT presynapse by including individuals diagnosed with MDD and SCH, in addition to BD, both with and without a history of suicide attempt. Our aim was to assess whether model-derived differences in 5-HT-related molecular species reflect suicide attempt status or are more closely associated with psychiatric diagnosis.
2. Materials and Methods
2.1. Study Participants
The study included 392 unrelated psychiatric patients diagnosed with BD (n = 101, 25.77%), MDD (n = 148, 37.76%) or SCH (n = 143, 36.48%) using the Structured Clinical Interview for DSM-IV Axis I Disorders [26], described in our previous study [27]. Additionally, 140 unaffected individuals were examined using the same interview. The patients were recruited after five weeks of hospitalization at the Department of Psychiatry, University Clinical Centre of Serbia, between 2006 and 2016. Inclusion criteria were a confirmed DSM-IV diagnosis, sociodemographic data (sex and age), and a history of suicide attempts. Exclusion criteria included the presence of other psychiatric disorders, neurological disorders, or unstable somatic conditions (Figure 1). Patients were categorized according to suicide attempt status. Patients with a history of suicide attempt (SA, n = 175, 44.64%) were hospitalized following an attempt, while the patients without a history of suicide attempt (non-SA, n = 217, 55.36%) were hospitalized due to recurrence of their primary psychiatric disorder and without a history of suicide attempts. All participants provided written informed consent. Ethical approval was obtained from the Ethics Committee of the University Clinical Centre of Serbia (Decision no. 340/4; 21 July 2021). The study was conducted in accordance with the Declaration of Helsinki.
2.2. Genotyping
Peripheral blood samples from patients with MDD and SCH were collected and genotyped, as described in detail in Radenkovic et al. [24]. We selected five genetic variants known to influence 5-HT metabolism: three single-nucleotide polymorphisms in the TPH2 gene (rs111798998, rs4290270, rs7305115), the 5-HT transporter-linked polymorphic region (5-HTTLPR) in the SLC6A4 gene, and the upstream variable number of tandem repeats (uVNTR) in the MAOA gene [28,29,30,31,32]. Chromosomal locations and allele frequencies for each variant in the general population are provided in Table S1. Genotype data for BD patients and unaffected individuals were obtained from our previous study [24]. Approximately 10% of all DNA samples were randomly selected for duplicate analysis. The results showed complete concordance.
2.3. Dynamic 5-HT Presynapse Model Simulation and Extraction of Model-Derived Features
A detailed description of the developed model of 5-HT presynapse, including its structure, parameterization, and the integration of genotype-dependent effects, is provided in Radenkovic et al. [24]. Briefly, the model consists of eight differential equations that quantitatively represent reactions catalyzed by TPH2, SERT and MAOA. We incorporated the coefficient Cgenotype which adjusts the activity of these proteins based on individual genotypes the functionally relevant variants: TPH2 (rs111798998, rs4290270, rs7305115), SLC6A4 (5-HTTLPR), and MAOA (uVNTR). These variants modulate gene expression in an allele-specific manner, influencing mRNA levels, as measured through allelic imbalance and luciferase reporter assays [28,29,30,31,32], and thereby affecting 5-HT synthesis, reuptake, and degradation. Specifically, rs111798998 G and rs7305115 A increase TPH2 mRNA expression ~3- and 1.7-fold, respectively, while rs4290270 A decreases expression ~1.4-fold. The SLC6A4 5-HTTLPR L allele increases transporter mRNA ~3-fold, and the MAOA uVNTR 4R and 3.5R alleles increase MAOA mRNA 5–6-fold. These genetically determined differences in enzyme/transporter expression are incorporated into the model as variations in protein abundance, thereby altering the concentrations and temporal dynamics of 5-HT–related molecular species. This in turn allowed for the simulation of individual-specific 5-HT dynamics and the calculation of the concentrations of 5-HT-related molecular species: 5-HTP, fc5-HT, v5-HT, e5-HT, and 5-HIAA. We applied this model of 5-HT presynapse to MDD and SCH patient groups, while the simulation data for BD patients and unaffected individuals were retrieved from our previous work [24].
Simulation of the model resulted in an output consisting of raw time series data for each of the five molecular species, simulated for every study participant. Given that direct comparisons between individuals or diagnostic groups were not possible due to the complexity of the raw time series data, we extracted a set of descriptive statistical measures for each molecular species and each participant. Specifically, we summarized the time series data by calculating the mean, median, standard deviation, maximum, skewness and kurtosis. These features were selected based on their ability to represent different aspects of time series data, as shown by Guo et al. [33]. Mean and median values represent measures of central tendency and reflect the average concentrations of molecular species over the course of the simulation. Standard deviation and maximum values reflect the dispersion and range of the time series data and capture its variability and peak levels, respectively. Skewness (degree of asymmetry in the distribution) and kurtosis (degree of peakedness and presence of outliers) represent the shape of the time series and provide important supplementary information for a comprehensive characterization of the entire time series. By extracting these six statistical measures for each of the five molecular species (5-HTP, fc5-HT, v5-HT, e5-HT, and 5-HIAA), we obtained a set of 30 model-derived features that was used for subsequent statistical analyses.
2.4. Statistical Analysis
All statistical analyses were conducted using R (v.4.1.0) and Python3 (v.3.11.4). The distributions of age and model-derived features were assessed for normality using Q–Q plots and the Shapiro–Wilk test. Differences in age between SA and non-SA patients were evaluated using the Mann–Whitney U test, while comparisons involving both patient groups and unaffected individuals were conducted using the Kruskal–Wallis test. Differences in sex distribution were assessed using the chi-square test of independence. All model-derived features were compared between SA and non-SA patients, and unaffected individuals using the Kruskal–Wallis test.
To examine the joint association of suicide attempt status and psychiatric diagnosis (BD, MDD, and SCH) on model-derived features, we used the Aligned Rank Transform (ART) ANOVA, a nonparametric statistical test that allows factor analysis of data that do not meet normality assumptions. It was implemented via the ARTool package in R (v.0.11.2) [34],
3. Results
3.1. Overview of Study Participants’ Data
Our study included 392 unrelated psychiatric patients diagnosed with BD (n = 101, 25.77%), MDD (n = 148, 37.76%), or SCH (n = 143, 36.48%). Approximately 45% of the patients had a history of suicide attempts. Additionally, a previously described cohort of 140 unaffected individuals was included as a control group [24]. The demographic characteristics of study participants are shown in Table 1. There were no significant differences in age (Mann–Whitney U test: U = 20,007.00, p = 0.361) or sex (Chi-square test: χ2 = 0.25, p = 0.619) between SA and non-SA patients. A comparison of age (Kruskal–Wallis test: H = 4.76, p = 0.093) and sex (Chi-square test: χ2 = 0.43, p = 0.805) across all three groups (SA, non-SA patients and unaffected individuals) also revealed no significant differences.
3.2. 5-HT Dynamic Model Simulation Results
Allele and genotype frequencies for the analyzed TPH2 variants (rs111798998, rs4290270, and rs7305115), the SLC6A4 variant 5-HTTLPR, and MAOA uVNTR variant in all study participants are given in Table S2. For each participant, we obtained the time-dependent output of the computational 5-HT presynapse model [24] showing the changes in concentrations of 5-HTP, fc5-HT, v5-HT, e5-HT, and 5-HIAA over the simulation period. Next, each time series was summarized using the statistical measures mean, median, standard deviation, maximum, skewness and kurtosis. The mean values of these measures for all groups stratified by diagnosis and suicide attempt status are given in Table S3.
To evaluate whether the 5-HT presynapse model-derived measures reflect suicide attempt status, we compared their values between three groups: all SA patients, all non-SA patients and unaffected individuals. No statistically significant differences were observed (Kruskal–Wallis test, all p > 0.05, Table 2). Next, we examined the potential interaction between suicide attempt status and psychiatric diagnosis in the patient group. A two-way ART ANOVA was performed with psychiatric diagnosis and suicide attempt status as factors to examine both their main and interaction effects on model-derived measures. The analysis revealed no significant main effects of suicide attempt status across any of the measures (all p-values > 0.05; Table S4). We observed a significant main effect of psychiatric diagnosis on four 5-HIAA-related measures: mean (F = 4.61, p = 0.011), median (F = 4.54, p = 0.011), maximum (F = 4.62, p = 0.010) and standard deviation (F = 4.49, p = 0.012). Post hoc comparisons revealed that individuals with BD had significantly lower 5-HIAA values across these four measures compared to individuals with SCH (mean: p = 0.013; median: p = 0.013; maximum: p = 0.014; standard deviation: p = 0.014) (Figure 1). MDD patients also showed lower values compared to SCH patients for the same 5-HIAA measures, with differences approaching statistical significance (mean: p = 0.060; median: p = 0.070; maximum: p = 0.054; standard deviation: p = 0.066). Differences between BD and MDD were not significant (all p > 0.05). This may be due to the observed opposite pattern of 5-HIAA mean, median, maximum, and standard deviation between SA and non-SA patients in MDD and BD groups (Figure 2 and Table S4).
In addition to the main effects of diagnosis on 5-HIAA measures, we observed a significant interaction between diagnosis and suicide attempt status for 5-HIAA skewness (F = 4.38, p = 0.013) (Figure 3). Moreover, several other model-derived measures showed trends toward an interaction between diagnosis and suicide attempt status, including fc5-HT (mean: p = 0.064; median: p = 0.084; maximum: p = 0.057; standard deviation: p = 0.065), v5-HT (mean: p = 0.067; maximum: p = 0.054; standard deviation: p = 0.063), e5-HT (median: p = 0.087), and 5-HIAA (mean: p = 0.087; maximum: p = 0.074; kurtosis: p = 0.099) (Table S4).
Taken together, these findings suggest that the 5-HT model-derived features predominantly reflect psychiatric diagnosis, as significant differences were observed primarily between the diagnostic groups. Although suicide attempt status alone was not a statistically significant factor, its influence appears to be diagnosis-specific.
4. Discussion
In the present study, we used a previously developed dynamic model of 5-HT presynapse to study 5-HT dynamics beyond conventional genetic associations, since the model integrates functionally validated variants with experimentally demonstrated effects on TPH2, SLC6A4, and MAOA expression into a mechanistic framework [24].
We applied the model to a large, diagnostically diverse cohort, including individuals with BD, MDD, SCH, and unaffected individuals, and showed that model-derived features were associated primarily with diagnosis, rather than suicide attempt status. Furthermore, we did not observe significant differences in age or sex between patients stratified by suicide attempt status.
Among five molecular species derived from the model, 5-HIAA emerged as the most informative for differentiating diagnostic groups. Specifically, we observed a significant main effect of diagnosis on four measures of 5-HIAA dynamics—mean, median, maximum, and standard deviation, suggesting their primary association with psychiatric diagnosis. BD patients exhibited significantly reduced levels of these measures compared to SCH, consistent with prior findings [6,16,24,35,36]. Moreover, we observed a trend of lower levels of the same 5-HIAA measures in MDD patients. Interestingly, MDD patients demonstrated an opposite pattern when stratified by suicide attempt status compared to the corresponding groups in BD and SCH patients, which aligns with the inconsistent findings reported in previous studies. Some studies observed reduced 5-HIAA levels in drug-naïve patients or after SSRI treatment [37,38], whereas others reported elevated 5-HIAA levels in specific subgroups [39,40]. These findings suggest that serotonergic profiles in MDD are heterogeneous and may be influenced by other moderating factors including medication status, symptom severity, and underlying neurobiological differences [41].
Furthermore, large-scale genetic studies, including GWAS and Mendelian randomization analyses, highlight a substantial shared genetic architecture between SCH and BD which only partially overlaps with MDD [23], supporting our observation that MDD differs from BD and SCH in relation to suicidal behavior [21,22,23]. Specifically, the genetic architecture of MDD correlates strongly with self-harm, including suicide attempt, but shows a weaker association with completed suicide [21]. Moreover, genetic effects of MDD can act both directly and indirectly through intermediate phenotypes such as insomnia [22], which itself is associated with increased suicide risk. Notably, serotonergic signaling through 5-HT receptors plays an important role in sleep regulation, suggesting a potential relationship between 5-HT dysregulation, sleep disturbances, and suicide attempts. Taken together, these findings indicate that the genetic architecture of MDD likely reflects both direct and indirect genetic influences on 5-HT pathways in the presynapse.
Analysis of 5-HIAA time-series skewness offers further insight into temporal dynamics of 5-HT metabolism in the presynapse. While the calculated mean, median, and maximum values reflect overall quantity of 5-HIAA and can be directly compared to empirical measurements, skewness reflects the timing of its accumulation in the system. In our model, 5-HIAA removal is held constant across individuals, while synthesis varies depending on genotype [24]. Consequently, the skewness of the 5-HIAA concentration time profile primarily reflects the synthesis rate. A more negative skew indicates a delayed accumulation, with concentration rising gradually and peaking later, whereas a less negative skew corresponds to earlier peak levels. We observed a significant interaction between diagnosis and suicide attempt status for 5-HIAA skewness (p = 0.013), suggesting that the timing of its accumulation may differ depending on both clinical diagnosis and history of suicide attempts.
Within each diagnostic group, subtle differences in 5-HIAA skewness were observed between patients grouped by suicide attempt status. MDD SA patients had on average slightly earlier 5-HIAA peaks (skewness –0.40) compared to non-SA (skewness –0.41), whereas BD patients showed the opposite pattern (skewness –0.41 in SA versus –0.40 in non-SA patients). Nevertheless, although these differences are modest, they reflect nuanced shifts in the timing of 5-HT metabolism, which may influence its accumulation, turnover, and long-term depletion, with potential implications for vulnerability to suicide attempt. Earlier 5-HIAA peaks combined with higher 5-HIAA concentrations suggest higher 5-HT turnover in MDD. This is consistent with reports of elevated turnover in unmedicated MDD patients [40], MDD patients with comorbid panic disorder [42], and with findings of higher 5-HIAA levels in MDD compared to BD in acute phase of the disorder [36]. Conversely, our results suggest lower 5-HT turnover in BD, in line with studies showing reduced 5-HIAA measurements during depressive and manic episodes compared to MDD and healthy controls [36], and with decreased CSF 5-HIAA in BD patients with a history of suicide attempts [43,44]. SCH patients exhibited minimal variation, with skewness values remaining close to –0.40 regardless of suicide attempt status, suggesting more stable serotonergic dynamics and supporting the view that 5-HT dysfunction may play a less central role in SCH pathophysiology [45,46]. To our knowledge, direct published measurements of the 5-HT degradation speed in psychiatric conditions appear limited.
By incorporating genetic variants in TPH2, SLC6A4, and MAOA genes, our model captures individual differences in 5-HT synthesis, reuptake, and degradation. The results reveal distinct serotonergic patterns associated with diagnosis, suicide attempt status, and their interaction, highlighting complex, diagnosis-specific alterations linked to suicidality. Furthermore, an overlap exists with other traits, such as genetic liability to substance use, alcohol abuse, insomnia, and neurodevelopmental disorders including ADHD, OCD, and autism [21,22,23]. This suggests that genetic liability for major psychiatric disorders may influence suicidal behaviors through both disorder-specific and shared mechanisms. Traditional group-level analyses often overlook important inter-individual variability in psychiatric disorders. In contrast, our personalized, genotype-informed simulations detect subtle, diagnosis-specific 5-HT dynamics related to suicidal behavior. Together, these results demonstrate that stratifying individuals by both genotype and diagnosis provides deeper insight into the serotonergic mechanisms of suicidality, offering a promising path toward personalized psychiatry and improved risk assessment. Evidence from functional and structural neuroimaging studies supports this implication. Shared disruptions in the cerebellum, thalamus, hippocampus, and cortical areas were observed in MDD and SCH, alongside diagnosis-specific alterations in the prefrontal cortex, amygdala, and temporal poles [47]. Structural changes have also been reported in individuals with a history of suicide attempt, including reduced cortical thickness [48], decreased brain volume [49], and increased activity in HTR1A-enriched regions such as the right superior temporal gyrus [50]. These findings suggest that subtle, diagnosis-specific shifts in 5-HT metabolism may have functional consequences in neural circuits involved in executive function and suicidal behavior.
Although our model incorporates kinetic parameters from the experimental literature and was validated both by comparison with other published models and by comparing simulated levels of 5-HT molecular species to published experimental measurements in a cohort of 140 unaffected individuals [24], several limitations of the study should be acknowledged. First, the model focuses exclusively on 5-HT pathways and a small set of functional genetic variants, which cannot capture the full genetic architecture influencing suicide risk and psychiatric diagnoses. Due to this, we were unable to capture the effect of gene–environment interactions or the effects of other neurotransmitter systems, such as the dopamine system. The existing model could be extended to include additional genes and variants within the 5-HT pathway, assuming well-characterized functional parameters for each variant, supported by experimental evidence. This could make the model more biologically realistic and potentially more precise by capturing a broader spectrum of genetic influences. However, incorporating multiple genes further increases mathematical complexity, computational requirements, and the likelihood of non-linear interactions, which could make the system more difficult to interpret and more challenging to validate against empirical data. Moreover, the individual effects of the selected genetic variants are inherently small, and the resulting changes in molecular species concentrations are correspondingly modest. Although these small alterations might appear negligible in magnitude, they are biologically relevant given the high sensitivity of 5-HT signaling pathways. Such fine-scale modulation can have significant downstream effects on receptor activation, neuronal excitability, and network dynamics. Nevertheless, detecting and interpreting these subtle genotype-driven differences remain challenging, particularly in the context of complex, multifactorial psychiatric disorders. Furthermore, our sample size limited the statistical power to detect subtle effects associated with phenotypic subgroups and strata, as well as the effects of the disease duration, prescribed medication, or means of suicide attempt.
Future work should extend the model to include additional genetic variants in serotonergic and related pathways and should integrate longitudinal clinical data, such as mood fluctuations, medication status, and behavioral outcomes. Applying the model in larger patient cohorts may help to further elucidate robust interactions between the elements of the 5-HT presynapse and improve its predictive utility for suicide risk stratification.
Conceptualization, D.S.-P., J.P. and L.R.; methodology, L.R.; software, L.R.; validation, L.R.; formal analysis, L.R. and J.P.; investigation, L.R.; resources, M.P.-S. and M.I.; data curation, L.R.; writing—original draft preparation, L.R.; writing—review and editing, J.P., G.B., M.I. and D.S.-P.; visualization, L.R.; supervision, J.P. and D.S.-P.; funding acquisition, D.S.-P. All authors have read and agreed to the published version of the manuscript.
The study was conducted in accordance with the Declaration of Helsinki, and approved by the Ethics Committee of University Clinical Centre of Serbia (reference number 340/4 from 21 July 2021).
Informed consent was obtained from all subjects involved in the study.
The datasets generated during the current study that includes patient genotype information, is not publicly available due to privacy concerns regarding personal genetic data. These datasets are available from the corresponding author upon reasonable request.
The authors declare no conflict of interest.
The following abbreviations are used in this manuscript:
| BD | Bipolar disorder |
| MDD | Major depressive disorder |
| SCH | Schizophrenia |
| 5-HT | Serotonin |
| 5-HIAA | Serotonin degradation product 5-hydroxy-3-indolacetic acid |
| CSF | Cerebrospinal fluid |
| GWAS | Genome wide association study |
| 5-HTP | Serotonin precursor 5-hydroxytryptophan |
| TPH2 | Tryptophan hydroxylase 2 |
| fc-5HT | Free cellular serotonin |
| v5-HT | Serotonin stored in the synaptic vesicle |
| e5-HT | Extracellular serotonin |
| SERT | Serotonin transporter |
| MAOA | Monoamine oxidase A |
| SA | Patients with a history of suicide attempt |
| non-SA | Patients without a history of suicide attempt |
| 5-HTTLPR | 5-HT transporter linked polymorphic region |
| uVNTR | Upstream variable number tandem repeat |
| ART | Aligned rank transform |
Footnotes
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
Figure 1 Flow diagram of participant inclusion and exclusion criteria.
Figure 2 5-hydroxyindoleacetic acid (5-HIAA) mean, median, maximum and standard deviation in patients with BD, MDD and SCH, with and without a history of suicide attempt. BD—bipolar disorder; MDD—major depressive disorder; SCH—schizophrenia.
Figure 3 Interaction effect of diagnosis and suicide attempt status on 5-hydroxyindoleacetic acid (5-HIAA) skewness in patients with BD, MDD and SCH, with and without a history of suicide attempt. BD—bipolar disorder; MDD—major depressive disorder; SCH—schizophrenia.
Demographic data of study participants.
| BD | MDD | SCH | Total | Unaffected | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| SA | non-SA | SA | non-SA | SA | non-SA | SA | non-SA | p-value 1 | n = 140 | p-value 2 | |
| Age 3 ± SD | 43.74 ± 11.7 | 39.05 ± 10.9 | 47.91 ± 9.7 | 50.99 ± 8.2 | 31.11 ± 8.7 | 35.47 ± 9.5 | 42.63 ± 11.6 | 41.53 ± 11.7 | 0.361 4 | 40.34 ± 11.19 | 0.093 5 |
| Sex (n, %) | |||||||||||
| female | 34 (73.9%) | 43 (78.2%) | 55 (72.4%) | 44 (61.1%) | 29 (54.7%) | 53 (58.9%) | 118 (67.4%) | 140 (64.5%) | 0.619 6 | 48 (34.29%) | 0.805 6 |
| male | 12 (26.1%) | 12 (21.8%) | 21 (27.6%) | 28 (38.9%) | 24 (45.3%) | 37 (41.1%) | 57 (32.6%) | 77 (35.5%) | 92 (65.71%) | ||
BD—bipolar disorder; MDD—major depressive disorder; SCH—schizophrenia; SA—patients with a history of suicide attempt; non-SA—patients without a history of suicide attempt. 1—Comparison between patients with and without suicide attempts; 2—Comparison between unaffected individuals, patients with and without suicide attempts; 3—Age is given in years; 4—Mann–Whitney U test; 5—Kruskal–Wallis test; 6—Pearson’s χ2 test.
Average values of model-derived statistical measures in unaffected individuals, patients with and without a history of suicide attempts.
| Unaffected | SA | Non-SA | p-Value 1 | ||
|---|---|---|---|---|---|
| 5-HTP | mean | 13.63 | 13.67 | 13.65 | 0.641 |
| median | 6.55 | 6.58 | 6.57 | 0.635 | |
| maximum | 42.24 | 42.36 | 42.32 | 0.549 | |
| standard deviation | 14.58 | 14.63 | 14.61 | 0.583 | |
| skewness | 0.79 | 0.79 | 0.79 | 0.637 | |
| kurtosis | 2.09 | 2.09 | 2.09 | 0.624 | |
| fc5-HT | mean | 0.89 | 0.90 | 0.89 | 0.348 |
| median | 0.57 | 0.58 | 0.57 | 0.337 | |
| maximum | 2.40 | 2.43 | 2.42 | 0.375 | |
| standard deviation | 0.83 | 0.84 | 0.84 | 0.363 | |
| skewness | 0.61 | 0.60 | 0.60 | 0.523 | |
| kurtosis | 1.85 | 1.84 | 1.85 | 0.567 | |
| v5-HT | mean | 2.49 | 2.52 | 2.51 | 0.347 |
| median | 1.69 | 1.71 | 1.71 | 0.489 | |
| maximum | 6.50 | 6.55 | 6.53 | 0.376 | |
| standard deviation | 2.26 | 2.28 | 2.28 | 0.345 | |
| skewness | 0.55 | 0.54 | 0.55 | 0.432 | |
| kurtosis | 1.77 | 1.77 | 1.77 | 0.558 | |
| e5-HT | mean | 0.07 | 0.07 | 0.07 | 0.066 |
| median | 0.04 | 0.04 | 0.04 | 0.415 | |
| maximum | 0.20 | 0.20 | 0.20 | 0.273 | |
| standard deviation | 0.07 | 0.07 | 0.07 | 0.475 | |
| skewness | 0.65 | 0.65 | 0.65 | 0.533 | |
| kurtosis | 1.90 | 1.89 | 1.90 | 0.554 | |
| 5-HIAA | mean | 0.61 | 0.57 | 0.59 | 0.725 |
| median | 0.64 | 0.60 | 0.61 | 0.771 | |
| maximum | 1.01 | 0.95 | 0.97 | 0.753 | |
| standard deviation | 0.30 | 0.28 | 0.29 | 0.704 | |
| skewness | −0.40 | −0.40 | −0.40 | 0.537 | |
| kurtosis | 2.11 | 2.11 | 2.11 | 0.353 |
SA—patients with a history of suicide attempt; non-SA—patients without a history of suicide attempt; 5-HTP—5-hydroxytryptophan; fc5-HT—free cellular serotonin (5-HT); v5-HT—vesicular 5-HT; e5-HT—extracellular 5-HT; 5-HIAA—5-hydroxyindoleacetic acid. 1—Kruskal–Wallis test. Mean, median, maximum, and standard deviation are in given in μM units; skewness and kurtosis are unitless.
Supplementary Materials
The following supporting information can be downloaded at:
1. Turecki, G.; Brent, D.A. Suicide and Suicidal Behaviour. Lancet; 2016; 387, pp. 1227-1239. [DOI: https://dx.doi.org/10.1016/S0140-6736(15)00234-2] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/26385066]
2. Favril, L.; Yu, R.; Geddes, J.R.; Fazel, S. Individual-Level Risk Factors for Suicide Mortality in the General Population: An Umbrella Review. Lancet Public Health; 2023; 8, pp. e868-e877. [DOI: https://dx.doi.org/10.1016/S2468-2667(23)00207-4] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/37898519]
3. Baldessarini, R.J.; Hennen, J. Genetics of Suicide: An Overview. Harv. Rev. Psychiatry; 2004; 12, pp. 1-13. [DOI: https://dx.doi.org/10.1080/10673220490425915] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/14965851]
4. Van Heeringen, K.; Mann, J.J. The Neurobiology of Suicide. Lancet Psychiatry; 2014; 1, pp. 63-72. [DOI: https://dx.doi.org/10.1016/S2215-0366(14)70220-2]
5. Lucki, I. The Spectrum of Behaviors Influenced by Serotonin. Biol. Psychiatry; 1998; 44, pp. 151-162. [DOI: https://dx.doi.org/10.1016/S0006-3223(98)00139-5]
6. Mann, J.J. Neurobiology of Suicidal Behaviour. Nat. Rev. Neurosci.; 2003; 4, pp. 819-828. [DOI: https://dx.doi.org/10.1038/nrn1220]
7. Mann, J.J. The Serotonergic System in Mood Disorders and Suicidal Behaviour. Philos. Trans. R. Soc. B; 2013; 368, 20120537. [DOI: https://dx.doi.org/10.1098/rstb.2012.0537]
8. Bengoechea-Fortes, S.d.l.P.; Ramírez-Expósito, M.J.; Martínez-Martos, J.M. Suicide, Neuroinflammation and Other Physiological Alterations. Eur. Arch. Psychiatry Clin. Neurosci.; 2023; 274, pp. 1037-1049. [DOI: https://dx.doi.org/10.1007/s00406-023-01584-z]
9. Stanley, M.; Stanley, B.; Traskman-Bendz, L.; Mann, J.J.; Meyendorff, E. Neurochemical Findings in Suicide Completers and Suicide Attempters. Suicide Life-Threat. Behav.; 1986; 16, pp. 286-300. [DOI: https://dx.doi.org/10.1111/j.1943-278X.1986.tb00356.x]
10. Underwood, M.D.; Khaibulina, A.A.; Ellis, S.P.; Moran, A.; Rice, P.M.; Mann, J.J.; Arango, V. Morphometry of the Dorsal Raphe Nucleus Serotonergic Neurons in Suicide Victims. Biol. Psychiatry; 1999; 46, pp. 473-483. [DOI: https://dx.doi.org/10.1016/S0006-3223(99)00043-8] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/10459396]
11. Wasserman, D.; Wasserman, J.; Rujescu, D.; Sokolowski, M. Neurobiology and the Genetics of Suicide. Oxford Textbook of Suicidology and Suicide Prevention; Wasserman, D.; Wasserman, C.; Wasserman, D. Oxford University Press: Oxford, UK, 2021; pp. 175-196. ISBN 978-0-19-883444-1
12. Stanley, M.; Stanley, B. Biochemical Studies in Suicide Victims: Current Findings and Future Implications. Suicide Life-Threat. Behav.; 1989; 19, pp. 30-42. [DOI: https://dx.doi.org/10.1111/j.1943-278X.1989.tb00364.x] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/2565612]
13. Bach, H.; Huang, Y.-Y.; Underwood, M.D.; Dwork, A.J.; Mann, J.J.; Arango, V. Elevated Serotonin and 5-HIAA in the Brainstem and Lower Serotonin Turnover in the Prefrontal Cortex of Suicides. Synapse; 2014; 68, pp. 127-130. [DOI: https://dx.doi.org/10.1002/syn.21695]
14. Pare, C.M.; Yeung, D.P.; Price, K.; Stacey, R.S. 5-Hydroxytryptamine, Noradrenaline, and Dopamine in Brainstem, Hypothalamus, and Caudate Nucleus of Controls and of Patients Committing Suicide by Coal-Gas Poisoning. Lancet; 1969; 2, pp. 133-135. [DOI: https://dx.doi.org/10.1016/S0140-6736(69)92442-8]
15. Shaw, D.M.; Camps, F.E.; Eccleston, E.G. 5-Hydroxytryptamine in the Hind-Brain of Depressive Suicides. Br. J. Psychiatry; 1967; 113, pp. 1407-1411. [DOI: https://dx.doi.org/10.1192/bjp.113.505.1407]
16. Åsberg, M. Neurotransmitters and Suicidal Behavior.: The Evidence from Cerebrospinal Fluid Studies. Ann. N. Y. Acad. Sci.; 1997; 836, pp. 158-181. [DOI: https://dx.doi.org/10.1111/j.1749-6632.1997.tb52359.x] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/9616798]
17. Ruderfer, D.M.; Walsh, C.G.; Aguirre, M.W.; Tanigawa, Y.; Ribeiro, J.D.; Franklin, J.C.; Rivas, M.A. Significant Shared Heritability Underlies Suicide Attempt and Clinically Predicted Probability of Attempting Suicide. Mol. Psychiatry; 2020; 25, pp. 2422-2430. [DOI: https://dx.doi.org/10.1038/s41380-018-0326-8]
18. Lybech, L.K.M.; Calabró, M.; Briuglia, S.; Drago, A.; Crisafulli, C. Suicide Related Phenotypes in a Bipolar Sample: Genetic Underpinnings. Genes; 2021; 12, 1482. [DOI: https://dx.doi.org/10.3390/genes12101482]
19. Kimbrel, N.A.; Ashley-Koch, A.E.; Qin, X.J.; Lindquist, J.H.; Garrett, M.E.; Dennis, M.F.; Hair, L.P.; Huffman, J.E.; Jacobson, D.A.; Madduri, R.K.
20. Docherty, A.R.; Mullins, N.; Ashley-Koch, A.E.; Qin, X.; Coleman, J.R.; Shabalin, A.; Kang, J.; Murnyak, B.; Wendt, F.; Adams, M.
21. Colbert, S.M.C.; Hatoum, A.S.; Shabalin, A.; Li, Q.S.; Coon, H.; Nelson, E.C.; Agrawal, A.; Docherty, A.R.; Johnson, E.C. Exploring the Genetic Overlap of Suicide-Related Behaviors and Substance Use Disorders. Am. J. Med. Genet.; 2021; 186, pp. 445-455. [DOI: https://dx.doi.org/10.1002/ajmg.b.32880] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/34821019]
22. Nassan, M.; Daghlas, I.; Winkelman, J.W.; Dashti, H.S. International Suicide Genetics Consortium Saxena, R. Genetic Evidence for a Potential Causal Relationship between Insomnia Symptoms and Suicidal Behavior: A Mendelian Randomization Study. Neuropsychopharmacology; 2022; 47, pp. 1672-1679. [DOI: https://dx.doi.org/10.1038/s41386-022-01319-z] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/35538198]
23. Cabrera-Mendoza, B.; Aydin, N.; Fries, G.R.; Docherty, A.R.; Walss-Bass, C.; Polimanti, R. Estimating the Direct Effects of the Genetic Liabilities to Bipolar Disorder, Schizophrenia, and Behavioral Traits on Suicide Attempt Using a Multivariable Mendelian Randomization Approach. Neuropsychopharmacology; 2024; 49, pp. 1383-1391. [DOI: https://dx.doi.org/10.1038/s41386-024-01833-2]
24. Radenković, L.; Karanović, J.; Pantović-Stefanović, M.; Lazić, D.; Brajušković, G.; Ivković, M.; Pešović, J.; Savić-Pavićević, D. Dynamic Model of Serotonin Presynapse and Its Application to Suicide Attempt in Patients with Bipolar Disorder. Int. J. Mol. Sci.; 2025; 26, 4085. [DOI: https://dx.doi.org/10.3390/ijms26094085]
25. Ingalls, B.P. Mathematical Modelling in Systems Biology: An Introduction; MIT Press: Cambridge, MA, USA, 2013.
26. Pincus, H.A.; First, M.; Frances, A.; McQueen, L. Reviewing DSM-IV. Am. J. Psychiatry; 1996; 153, 850. [DOI: https://dx.doi.org/10.1176/ajp.153.6.850]
27. Karanović, J.; Šviković, S.; Pantović, M.; Durica, S.; Brajušković, G.; Damjanović, A.; Jovanović, V.; Ivković, M.; Romac, S.; Savić Pavićević, D. Joint Effect of ADARB1 Gene, HTR2C Gene and Stressful Life Events on Suicide Attempt Risk in Patients with Major Psychiatric Disorders. World J. Biol. Psychiatry; 2015; 16, pp. 261-271. [DOI: https://dx.doi.org/10.3109/15622975.2014.1000374]
28. Denney, R.M.; Koch, H.; Craig, I.W. Association between Monoamine Oxidase A Activity in Human Male Skin Fibroblasts and Genotype of the MAOA Promoter-Associated Variable Number Tandem Repeat. Hum. Genet.; 1999; 105, pp. 542-551. [DOI: https://dx.doi.org/10.1007/s004399900183]
29. Sabol, S.Z.; Hu, S.; Hamer, D. A Functional Polymorphism in the Monoamine Oxidase A Gene Promoter. Hum. Genet.; 1998; 103, pp. 273-279. [DOI: https://dx.doi.org/10.1007/s004390050816] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/9799080]
30. Lim, J.-E.; Pinsonneault, J.; Sadee, W.; Saffen, D. Tryptophan Hydroxylase 2 (TPH2) Haplotypes Predict Levels of TPH2 MRNA Expression in Human Pons. Mol. Psychiatry; 2007; 12, pp. 491-501. [DOI: https://dx.doi.org/10.1038/sj.mp.4001923] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/17453063]
31. Chen, G.-L.; Vallender, E.J.; Miller, G.M. Functional Characterization of the Human TPH2 5′ Regulatory Region: Untranslated Region and Polymorphisms Modulate Gene Expression in Vitro. Hum. Genet.; 2008; 122, pp. 645-657. [DOI: https://dx.doi.org/10.1007/s00439-007-0443-y]
32. Heils, A.; Teufel, A.; Petri, S.; Stöber, G.; Riederer, P.; Bengel, D.; Lesch, K.P. Allelic Variation of Human Serotonin Transporter Gene Expression. J. Neurochem.; 2002; 66, pp. 2621-2624. [DOI: https://dx.doi.org/10.1046/j.1471-4159.1996.66062621.x]
33. Guo, C.; Lu, M.; Chen, J. An Evaluation of Time Series Summary Statistics as Features for Clinical Prediction Tasks. BMC Med. Inform. Decis. Mak.; 2020; 20, 48. [DOI: https://dx.doi.org/10.1186/s12911-020-1063-x] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/32138733]
34. Wobbrock, J.O.; Findlater, L.; Gergle, D.; Higgins, J. The Aligned Rank Transform for Nonparametric Factorial Analyses Using Only Anova Procedures. Int. Conf. Hum. Factors Comput. Syst.; 2011; pp. 143-146. [DOI: https://dx.doi.org/10.1145/1978942.1978963]
35. Marx, W.; McGuinness, A.J.; Rocks, T.; Ruusunen, A.; Cleminson, J.; Walker, A.J.; Gomes-Da-Costa, S.; Lane, M.; Sanches, M.; Diaz, A.P.
36. Li, Y.; Wang, L.; Huang, J.; Zhang, P.; Zhou, Y.; Tong, J.; Chen, W.; Gou, M.; Tian, B.; Li, W.
37. Yoon, H.S.; Hattori, K.; Ogawa, S.; Sasayama, D.; Ota, M.; Teraishi, T.; Kunugi, H. Relationships of Cerebrospinal Fluid Monoamine Metabolite Levels With Clinical Variables in Major Depressive Disorder. J. Clin. Psychiatry; 2017; 78, pp. 947-956. [DOI: https://dx.doi.org/10.4088/JCP.16m11144]
38. Jayamohananan, H.; Kumar, M.K.M.; Aneesh, T.P. 5-HIAA as a Potential Biological Marker for Neurological and Psychiatric Disorders. Adv. Pharm. Bull.; 2019; 9, pp. 374-381. [DOI: https://dx.doi.org/10.15171/apb.2019.044]
39. Hoertel, N.; Cipel, H.; Blanco, C.; Oquendo, M.A.; Ellul, P.; Leaune, E.; Limosin, F.; Peyre, H.; Costemale-Lacoste, J.-F. Cerebrospinal Fluid Levels of Monoamines among Suicide Attempters: A Systematic Review and Random-Effects Meta-Analysis. J. Psychiatr. Res.; 2021; 136, pp. 224-235. [DOI: https://dx.doi.org/10.1016/j.jpsychires.2021.01.045] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/33618064]
40. Barton, D.A.; Esler, M.D.; Dawood, T.; Lambert, E.A.; Haikerwal, D.; Brenchley, C.; Socratous, F.; Hastings, J.; Guo, L.; Wiesner, G.
41. Suseelan, S.; Pinna, G. Heterogeneity in Major Depressive Disorder: The Need for Biomarker-Based Personalized Treatments. Adv. Clin. Chem.; 2023; 112, pp. 1-67. [DOI: https://dx.doi.org/10.1016/bs.acc.2022.09.001]
42. Sullivan, G.M.; Oquendo, M.A.; Huang, Y.-Y.; Mann, J.J. Elevated Cerebrospinal Fluid 5-Hydroxyindoleacetic Acid Levels in Women with Comorbid Depression and Panic Disorder. Int. J. Neuropsychopharmacol.; 2006; 9, pp. 547-556. [DOI: https://dx.doi.org/10.1017/S1461145705006231] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/16259647]
43. Young, L.; Warsh, J.J.; Kish, S.J.; Shannak, K.; Hornykeiwicz, O. Reduced Brain 5-HT and Elevated NE Turnover and Metabolites in Bipolar Affective Disorder. Biol. Psychiatry; 1994; 35, pp. 121-127. [DOI: https://dx.doi.org/10.1016/0006-3223(94)91201-7]
44. Sher, L.; Carballo, J.J.; Grunebaum, M.F.; Burke, A.K.; Zalsman, G.; Huang, Y.; John Mann, J.; Oquendo, M.A. A Prospective Study of the Association of Cerebrospinal Fluid Monoamine Metabolite Levels with Lethality of Suicide Attempts in Patients with Bipolar Disorder. Bipolar Disord.; 2006; 8, pp. 543-550. [DOI: https://dx.doi.org/10.1111/j.1399-5618.2006.00319.x]
45. Jiménez-Trejo, F.; Jiménez-García, K.L.; Canul-Medina, G. Serotonin and Schizophrenia: What Influences What?. Front. Psychiatry; 2024; 15, 1451248. [DOI: https://dx.doi.org/10.3389/fpsyt.2024.1451248]
46. Stahl, S.M. Beyond the Dopamine Hypothesis of Schizophrenia to Three Neural Networks of Psychosis: Dopamine, Serotonin, and Glutamate. CNS Spectr.; 2018; 23, pp. 187-191. [DOI: https://dx.doi.org/10.1017/S1092852918001013]
47. Yu, A.; Gao, Q.; Deng, Z.; Dang, Y.; Yan, C.; Chen, Z.; Li, F.; Zhao, S.; Liu, Y.; Bo, Q. Common and Unique Alterations of Functional Connectivity in Major Depressive Disorder and Bipolar Disorder. Bipolar Disord.; 2023; 25, pp. 289-300. [DOI: https://dx.doi.org/10.1111/bdi.13336] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/37161552]
48. Sarkinaite, M.; Gleizniene, R.; Adomaitiene, V.; Dambrauskiene, K.; Raskauskiene, N.; Steibliene, V. MRI Analysis of Brain Structures in Patients with History of First and Repeated Suicide Attempts: A Cross Sectional Study. Diagnostics; 2020; 11, 488. [DOI: https://dx.doi.org/10.3390/diagnostics11030488]
49. Campos, A.I.; Thompson, P.M.; Veltman, D.J.; Pozzi, E.; van Veltzen, L.S.; Jahanshad, N.; Adams, M.J.; Baune, B.T.; Berger, K.; Brosch, K.
50. Meda, N.; Miola, A.; Cattarinussi, G.; Sambataro, F. Whole-Brain Structural and Functional Neuroimaging of Individuals Who Attempted Suicide and People Who Did Not: A Systematic Review and Exploratory Coordinate-Based Meta-Analysis. Eur. Neuropsychopharmacol.; 2024; 79, pp. 66-77. [DOI: https://dx.doi.org/10.1016/j.euroneuro.2023.10.003]
51. Chen, S.; Francioli, L.C.; Goodrich, J.K.; Collins, R.L.; Kanai, M.; Wang, Q.; Alföldi, J.; Watts, N.A.; Vittal, C.; Gauthier, L.D.
52. Noskova, T.; Pivac, N.; Nedic, G.; Kazantseva, A.; Gaysina, D.; Faskhutdinova, G.; Gareeva, A.; Khalilova, Z.; Khusnutdinova, E.; Kovacic, D.K.
53. Samochowiec, A.; Chęć, M.; Kopaczewska, E.; Samochowiec, J.; Lesch, O.; Grochans, E.; Jasiewicz, A.; Bienkowski, P.; Łukasz, K.; Grzywacz, A. Monoamine oxidase a promoter variable number of tandem repeats (MAOA-uVNTR) in alcoholics according to Lesch typology. Int. J. Environ. Res. Public Health; 2015; 12, pp. 3317-3326. [DOI: https://dx.doi.org/10.3390/ijerph120303317] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/25809512]
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Details
; Brajušković Goran 1
; Ivković Maja 2
; Dušanka, Savić-Pavićević 1
; Pešović Jovan 1 1 University of Belgrade-Faculty of Biology, Centre for Human Molecular Genetics, Studentski Trg 16, 11000 Belgrade, Serbia; [email protected] (L.R.); [email protected] (G.B.); [email protected] (D.S.-P.)
2 Clinic for Psychiatry, University Clinical Centre of Serbia, Pasterova 2, 11000 Belgrade, Serbia; [email protected] (M.P.-S.); [email protected] (M.I.), University of Belgrade-Faculty of Medicine, Doktora Subotića 8, 11000 Belgrade, Serbia